
Third Quarter 2026 Earnings



November 3, 2026

Safe Harbor

This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, plans concerning business development opportunities, acquisitions or divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded hyperlink and is available on the “Financial Information” section of our website at www.revvity.com.

Key Takeaways


Innovation	Market	Performance
Launched 3-plex solution for **early detection of T1D** Announced acquisition of **Human Cell Design**	**Improving Pharma/Biotech** end market conditions **AI-related demand** continuing to build Strong **Diagnostic** trends outside of China	3Q financial performance **above expectations** Volume and operational efficiency drove **meaningful margin expansion** Strong **cash flow** and retired €500m note

A Scientific Solutions Company Helping to Solve The World's Greatest Health Challenges
From Discovery to Development, and Diagnosis to Cure

3Q26 Pro Forma* Revenue Highlights


Segments

Diagnostics Life Sciences




Geographic

AMERICAS APAC EU



Product Mix

Recurring Non-recurring




*Pro Forma excludes the impact of the China Immunodiagnostics business which the Company has agreed to divest

3Q26 Financial Results

PRO FORMA REVENUE	PRO FORMA ADJ. OP. MARGIN	PRO FORMA ADJ. EPS	FREE CASH FLOW
$710M	**29.4%**	**$1.37**	**$152M**
⬆ +7% y/y	**⬆ +340bps y/y**	**⬆ +21% y/y**	**$451M YTD**
Organic: +7% | M&A: +1% | FX: -1%	**Adj. Gross Margin:** 62.4% | +280bps y/y	**Adj. Tax Rate:** 18.2%	**YTD FCF % Adj. NI:** 105%
		Adj. Net Interest & Other: $21M	

Pro Forma excludes the impact of the China Immunodiagnostics business which the Company has agreed to divest; Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink

Life Sciences




PRO FORMA REVENUE	ADJUSTED OP. MARGINS
+9% Organic Growth	31.5%
Total: +11% | M&A: +2% | FX: 0%	+200bps y/y

- +LDD Pharma/Biotech & +MSD Academic/Gov't
- +HSD Life Sciences Solutions, with both reagents and instruments delivering growth ahead of expectations
- +DD software, driven by contract renewals and ARR growth
- Margin improvement yr/yr driven by volume leverage and favorable product mix

revvity

Pro Forma revenue excludes the impact of the China Immunodiagnostics business which the Company has agreed to divest; Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink

Diagnostics




PRO FORMA REVENUE	ADJUSTED OP. MARGINS
+5% Organic Growth	29.9%
Total: +4% | M&A: 0% | FX: -1%	+480bps y/y

- +HSD ImmunoDx with strength in the Americas
- +LSD Reproductive Health with +MSD growth ex-China
- Significant margin improvement yr/yr driven by volume leverage and benefit of operational efficiency
- Dx adj. Op. Margin includes 160bps headwind from China ImmunoDx


Pro Forma revenue excludes the impact of the China Immunodiagnostics business which the Company has agreed to divest; Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink

2026 Pro Forma* Financial Guidance

REVENUE	**~$2.86B**
	Total: ~6%
	Organic: ~5%
	FX: +0.5%, M&A: +0.75%
ADJUSTED OP. MARGIN	**~28.8%**
ADJUSTED EPS	**$5.40 - $5.45**
	Adj. net interest expense, other: ~$88M
	Adj. tax rate: ~18%
	Average diluted share count: ~112M



*Pro Forma excludes the impact of the China Immunodiagnostics business which the Company has agreed to divest



Revvity.com